ALEXANDRIA, Va., July 23 -- United States Patent no. 12,365,895, issued on July 22, was assigned to Genzyme Corp. (Cambridge, Mass.).
"Variant RNAi against alpha-synuclein" was invented by Bradford Elmer (Bridgewater, N.J.), Brenda Richards (Bridgewater, N.J.), Martine Latta-Mahieu (Paris), Maria Carmen Obinu (Paris), Veronique Taupin (Paris) and Veronique Blanchard (Paris).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are RNAi molecules for treating neurodegenerative synucleinopathies. In some embodiments, the RNAi molecules target expression of alpha-synuclein (SNCA). Further provided herein are expression constructs, vectors (e.g. rAAV), cells, viral particles, and pharmaceutical compositi...